Endocrine Abstracts

Introduction: There is growing real-world experience of the SGLT2 inhibitor class for type 2 diabetes mellitus (T2D). We performed an audit of clinico-biochemical effects of SGLT2 inhibitor use for patients with diabesity in the context of a tier-3 obesity service within a UK-based teaching hospital.Methods: We included patients with a confirmed diagnosis of T2D who had been treated with an SGLT2 inhibitor within licensed indications (monotherapy and add...

The importance of weight reduction in the management of diabesity is well-established. However, significant weight loss can be difficult to achieve without bariatric surgery, even within specialist tier 3 obesity services. Here we describe the case of a 52 year old man who presented to weight management clinic. He had made multiple weight loss attempts, but with little success. On presentation, his weight was 140.8 kg with a BMI of 40.3 kg/m2, and he had now been static at thi...

Variability in treatment response with respect to GLP1 agents is well-accepted but incompletely understood. In a specialist GLP-1 clinic at UHCW, we describe a case of improved therapeutic response following change in injection site. Currently, advice is injection in the abdomen or thigh.A 61 year old man was commenced on Liraglutide 1.2 mg subcutaneous OD injection, in 2013. Previously managed with glimepiride 4 mg and ...

Variability in treatment response with respect to GLP1 agents is well-accepted but incompletely understood. In a specialist GLP-1 clinic at UHCW, we describe a case of improved therapeutic response following change in injection site. Currently, advice is injection in the abdomen or thigh.A 61 year old man was commenced on Liraglutide 1.2 mg subcutaneous OD injection, in 2013. Previously managed with glimepiride 4 mg and ...

We present the case of a 58-year-old woman who presented 30 years ago. She was noted to have abdominal obesity, moon-face and skin bruising/thinning, as well as hypertension. Serum cortisol was elevated and she was presumed to have Cushing’s disease (although we have no record of dynamic tests or imaging from the time of her original presentation). Owing to her desire for future fertility, she underwent bilateral adrenalectomy at the age of 31 years. She received hydrocor...

Introduction: Therapeutic durability of GLP1-based therapies in patients with type 2 diabetes mellitus (T2D) is incompletely understood. Our aim was to explore the therapeutic effects of GLP1 based therapies in patients with T2D.Methods: This was a retrospective study on patients with T2D (n=55) who attend a specialist clinic at UHCW, Coventry, and who had been treated with the GLP1 based therapy, Liraglutide, for at least 6 months. A successful...